Link Cell Therapies Launches with Aim to Advance CAR-T Treatments for Solid and Liquid Tumors

Link Cell Therapies, a biotechnology oncology cell therapy company, has officially launched with the mission of accelerating the development of next-generation CAR-T therapies targeting both liquid and solid tumours. The company plans to apply innovations in cell engineering, tumor microenvironment modulation, and safety switches to overcome longstanding challenges that have limited CAR-T efficacy in solid malignancies. Link says its initial programs will advance through preclinical validation with IND-enabling goals, targeting tumor antigens with broad expression profiles and engineered features designed to improve persistence and reduce off-target toxicity.

Link’s strategy of combining advanced engineering and adaptive safety mechanisms aligns with competitors' efforts to target solid tumor niches. For developers and clinicians, the company’s entry underscores the evolving landscape of cellular therapies where addressing solid malignancies remains a key frontier. The LNK001 program is aimed at treating renal cell carcinoma with two unique antigens for RCC tumors. The unique technology could enable the development of multiple treatments for patients.

Posted by MedCloudInsider Editors on 12/15/2025